MRK · 10-Q · 2026Q3 · Full report
Share Repurchase Program
Merck & Co., Inc. · 2026-11-04 · Importance 42 · Surprise 24 · Matches filing data
Merck’s January 2025 authorization permits purchases of up to $10 billion of common stock and has no time limit. During the first nine months of 2026, the company repurchased $2.3 billion, or 19 million shares, under the program. Merck expects to repurchase approximately $3.0 billion of treasury shares during 2026. The remaining authorization was $5.1 billion as of September 30, 2026.
Key facts
- Merck expects to repurchase approximately $3.0 billion of treasury shares under its program during 2026; remaining authorization was $5.1 billion at September 30, 2026. source
- Merck's January 2025 authorization permits up to $10 billion of common-stock repurchases and has no time limit. source
- Merck repurchased $2.3 billion, or 19 million shares, in the first nine months of 2026 under its share-repurchase program. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | committed | -3.3% | Merck expects to repurchase approximately $3.0 billion of treasury shares under its program during 2026; remaining authorization was $5.1… |
| cash | negative | realized | -1.7% | Merck repurchased $2.3 billion, or 19 million shares, in the first nine months of 2026 under its share-repurchase program. |